Clinical trial NCT00272311 - References

Cardiovascular Diseases — Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

Citation(s)

•   Eidelman RS, Hebert PR, Weisman SM, Hennekens CH
  An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003 Sep 22;163(17):2006-10.
•   Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schröder H
  Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003 Sep 5;308(4):956-60.
•   Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R
  Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989 Oct;80(4):749-56. Review.
•   Hennekens CH, Dyken ML, Fuster V
  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997 Oct 21;96(8):2751-3.
•   Hennekens CH, Hollar D, Baigent C
  Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nat Clin Pract Cardiovasc Med. 2006 Jan;3(1):4-5.
•   Hennekens CH, Schror K, Weisman S, FitzGerald GA
  Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004 Sep 21;110(12):1706-8. Review.
•   Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P
  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999 Aug 24;100(8):793-8.
•   Mustard JF, Moore S, Packham MA, Kinlough-Rathbone RL
  Platelets, thrombosis and atherosclerosis. Prog Biochem Pharmacol. 1977;13:312-25.
•   Mustard JF, Packham MA, Kinlough-Rathbone RL
  Platelets and thrombosis in the development of atherosclerosis and its complications. Adv Exp Med Biol. 1978;102:7-30. Review.
•   Mustard JF, Packham MA
  The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemorrh. 1975 Jun 30;33(3):444-56.
•   Oberle S, Polte T, Abate A, Podhaisky HP, Schröder H
  Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998 May 18;82(9):1016-20.
•   Patrignani P, Filabozzi P, Patrono C
  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366-72.
•   Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA
  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002 Jul 16;106(3):388-91. Review.
•   Reilly IA, FitzGerald GA
  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987 Jan;69(1):180-6.
•   Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH
  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973-9. Erratum in: N Engl J Med 1997 Jul 31;337(5):356.
•   Roth GJ, Stanford N, Majerus PW
  Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073-6.
•   Steer KA, Wallace TM, Bolton CH, Hartog M
  Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997 Apr;77(4):333-7.
•   U
  S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002 Jan 15;136(2):157-60.
•   Williams A, Hennekens CH
  The role of aspirin in cardiovascular diseases--forgotten benefits? Expert Opin Pharmacother. 2004 Jan;5(1):109-15. Review.
•   Wu R, Lamontagne D, de Champlain J
  Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002 Jan 22;105(3):387-92.

A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)

Details for clinical trial NCT00272311